Skip To Main Content
Lucélia P. C. Schimidt on Muck Rack

Lucélia P. C. Schimidt

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lucélia P. C.

Contact Lucélia P. C., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Immunogenicity and safety of BNT162b2 vaccine in patients with juvenile immune mediated inflammatory disease

|
By Maria Teresa Terreri, Daniel Ferreira, Sandra Ribeiro, Camila Telles, Leonardo C. Campos, Gilda Ferreira, Ricardo M. Xavier, Odirlei André Monticielo, Emilia Sato, Viviane de Souza, Gleice Clemente, Valéria Valim, Carolina S. E. Gadelha, Aline C. M. da Fraga, Ketty L. L. L. Machado, Rita Elizabeth Checon, Yhasmin O. G. Moraes, Rodrigo P. V. de Rezende, Katia Lino, Lucélia P. C. Schimidt, Edgard T. dos Reis-Neto, Gecilmara S. Pileggi
| Nature Verified
Abstract COVID-19 vaccines have significantly reduced mortality and are safe for healthy children; however, research in pediatric populations with juvenile immune-mediated inflammatory diseases (IMIDs) is limited. The Brazilian multicenter longitudinal SAFER-Study evaluates immunogenicity and safety of the BNT162b2/Pfizer vaccine in IMID patients.
Open in Who Shared Issue with article?
See all 1 articles